Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02500615 · ClinicalTrials.gov registry record · Phase 1

The Effect of Electronic Cigarette (ECIG) Liquid Vehicles on ECIG Acute Effects

A Phase 1 study, sponsored by Virginia Commonwealth University.

Completed
Registry status
Phase 1
Development phase
41
Enrollment target

NCT02500615 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 41 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02500615, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.

COMPLETED
Registry status
Phase 1
Development phase
41 participants
Enrollment target

Study Summary

This study examines the acute effects in ECIG users of the two primary vehicles in ECIG liquids, propylene glycol and vegetable glycerin. Thirty experienced ECIG users will use an ECIG in five conditions that will differ only by the propylene glycol:vegetable glycerin ratio: 100:0, 70:30, 50:50, 30:70, and 0:100 (device voltage, heater resistance, liquid nicotine concentration, puff number, and interpuff interval all will be held constant). Plasma nicotine concentration, subjective effects, and puffing behaviors will be recorded in each condition.

Interventions

  • OTHER ECIG liquid vehicles

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2016-07
Est. Completion 2017-05-16
Phase Phase 1

Sponsor

Virginia Commonwealth University

558 total trials

What the Registry Record Tells You About NCT02500615

The ClinicalTrials.gov registry entry for NCT02500615 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which ECIG liquid vehicles is the first listed.

NCT02500615 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02500615 about?

NCT02500615 is a clinical study titled "The Effect of Electronic Cigarette (ECIG) Liquid Vehicles on ECIG Acute Effects". This study examines the acute effects in ECIG users of the two primary vehicles in ECIG liquids, propylene glycol and vegetable glycerin. Thirty experienced ECIG users will use an ECIG in five conditions that will differ only by the propylene glycol:vegetable glycerin ratio: 100:0, 70:30, 50:50, 30:...

What is the current status of trial NCT02500615?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2016-07. Estimated completion is 2017-05-16.

What interventions are being tested in trial NCT02500615?

The interventions under investigation include: ECIG liquid vehicles (OTHER).

Who is sponsoring clinical trial NCT02500615?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.